WO2024146536 - ANTI-MUC1 ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/146536
Publication Date
11.07.2024
International Application No.
PCT/CN2024/070253
International Filing Date
03.01.2024
Title **
[English]
ANTI-MUC1 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-MUC1 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
ZHANG, Yifu
SHANG, Chengzhang
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2023/070283
04.01.2023
CN
PCT/CN2023/082744
21.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4308 | |
| EPO | Filing, Examination, Granting | 76273 | |
| Japan | Filing, Examination, Granting | 4349 | |
| South Korea | Filing, Examination, Granting | 6747 | |
| USA | Filing, Examination, Granting | 25990 |
Total:
117,667
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are anti-MUCl (Mucin 1, cell surface associated) antibodies, antigen-binding fragments thereof, antibody-drug conjugate (ADC) derived therefrom, and the uses thereof.[French]
La présente divulgation concerne des anticorps anti-MUC1 (Mucine 1, associés à la surface cellulaire), des fragments de liaison à l'antigène de ceux-ci, un conjugué anticorps-médicament (ADC) dérivé de ceux-ci, ainsi que leurs utilisations.